glp-1 vs sglt2 weight loss Mapping the effectiveness and risks of receptor agonists Weight loss variability with SGLT2

46 personnes ont trouv ce commentaire utile Cet avis vous a t utile

Why this matters: The global obesity market is expanding rapidly GLP-1 drugs are generating multi-billion dollar annual revenues Demand continues to outpace supply in many regions Cost-efficient manufacturers now see a massive opportunity For Indias pharmaceutical ecosystem, this moment is strategic

On Monday, 24th November, Novo Nordisk published a press release, explaining that the Evoke and Evoke+ trials did not confirm superiority of semaglutide versus placebo in the reduction of progression of Alzheimers disease. Although the researchers did report significant reductions in biomarkers associated with Alzheimers, there was no reduction in disease progression in either trial

Researchers concluded that semaglutide was associated with a 15% reduction in fracture incidence. The full research has not been published yet, so the full limitations are not clear at this time

Overuse can disturb liver enzymes, especially in people who already have mild liver issues without knowing it